Related Experiment Videos
(-)Deprenyl (Selegiline): past, present and future
1Department of Pharmacology, Semmelweis University of Medicine, Budapest, Hungary.
Neurobiology (Budapest, Hungary)
|November 4, 2000
Summary
(-)Deprenyl (Selegiline) enhances catecholaminergic activity, slowing age-related decline in rats and benefiting Parkinson
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- (-)Deprenyl (Selegiline) is a selective catecholaminergic activity enhancer (CAE).
- Unlike amphetamines, it stimulates catecholaminergic neurons without depleting neurotransmitter stores.
- Its unique mechanism offers potential therapeutic benefits.
Purpose of the Study:
- To investigate the long-term effects of (-)Deprenyl on age-related decline.
- To evaluate its efficacy in neurodegenerative diseases like Parkinson's and Alzheimer's.
- To explore its potential as a prophylactic agent against age-related behavioral decline.
Main Methods:
- Administration of (-)Deprenyl to rats during their postdevelopmental phase.
- Clinical trials involving patients with early Parkinson's disease and Alzheimer's disease.
- Comparative analysis of treatment groups versus placebo and standard therapies.
Main Results:
- (-)Deprenyl prolonged lifespan and improved sexual and learning performances in rats.
- Delayed levodopa requirement in early Parkinson's patients and improved survival rates when combined with levodopa.
- Slowed disease progression in patients with moderately severe Alzheimer's disease.
Conclusions:
- (-)Deprenyl demonstrates significant benefits in slowing age-related decline and enhancing cognitive functions.
- It shows promise in managing Parkinson's and Alzheimer's diseases.
- Prophylactic use of (-)Deprenyl may mitigate age-related behavioral decline and reduce susceptibility to neurodegenerative conditions.